BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30

• Genetown

  Genzyme Corporation Provides Update on Cerezyme and Fabrazyme Supply

  September 23, 2009

   · 

  1 min read
• Business

  Governor Christine Gregoire Officially Dedicates New Albany Molecular Research, Inc. Research Facility in Bothell, Washington

  September 23, 2009

   · 

  1 min read
• Drug Development

  Lux Biosciences Reports Phase 1 Safety Results and Open Label Efficacy Results for LX214, a Potential Best-in-Class Treatment for Dry Eye

  September 23, 2009

   · 

  1 min read
• Drug Development

  Idera Pharmaceuticals, Inc. Presents Interim Data from Phase 1b Clinical Trial of IMO-2055 in Combination with Tarceva(R) and Avastin(R) in Non-Small Cell Lung Cancer

  September 23, 2009

   · 

  1 min read
• Deals

  Bederra Corporation in Talks to Acquire Basic Solutions

  September 23, 2009

   · 

  2 min read
• Drug Development

  Plexxikon Inc. Announces Encouraging Data from Phase 1 Extension Study of PLX4032 Showing Objective Responses in Metastatic Melanoma Patients

  September 23, 2009

   · 

  1 min read
• Business

  Bio-Matrix Scientific Group Inc. And Therinject Begin Development of Tumor Banking Facility in Conjunction with Cancer Therapeutic Vaccine

  September 23, 2009

   · 

  1 min read
• Biotech Bay

  Elixir Medical Announces Positive First-In-Man Results for Three Drug Eluting Coronary Stent Systems with Durable and Bioabsorbable Polymers

  September 23, 2009

   · 

  1 min read
• Drug Development

  Pluristem Therapeutics Doses First Patient in U.S. With Placenta-Derived Stem Cell Product PLX-PAD in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease

  September 23, 2009

   · 

  1 min read
• Drug Development

  MicroDose Therapeutx (formerly MicroDose Technologies Inc) Announces Initiation of Phase 1 Study with Inhaled Atropine as Antidote to Combat Effects of Nerve Agent Poisoning

  September 23, 2009

   · 

  1 min read